We can't find the internet
Attempting to reconnect
14011.2 PFLS-LS
14011.2 PFLS-LS
Zusammenfassung
Development of an organotypic high-throughput screening assay kit to determine predictability of anti-cancer drugs in 3D QGel
Weitere Texte
Abstract
This project brings together the start-up company QGel and academic cancer and matrix|biology experts in order to develop proven QGel technology into a 3D cell-based highthroughput|assay kit for primary patient-derived cancer cells. Commercially available anticancer|drugs will be tested on these tumor models grown in vitro with QGel technology.|Based on indications by cancer experts, QGel drug-tumor response data are collected and|compared to clinical data of these drugs.
Beteiligte
Colin Sanctuary
Wirtschaftspartner
colin.sanctuary@qgelbio.com
QGel SA Colin Sanctuary Bâtiment C / EPFL Innovation Park 1015 Lausanne VD CH
Matthias Lutolf
Kontaktperson
matthias.lutolf@epfl.ch
EPFL SV IBI LSCB Matthias Lutolf Station 15, Bâtiment Al 1109 1015 Lausanne VD CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2013-05-31
- Enddatum
- 2017-03-31
- Bewilligte Gesamtkosten
- CHF 395600.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- P004 Biochemistry, Metabolism 100.0%